Endothelin and endothelin antagonists in chronic kidney disease

Kidney International

Volumn 86, Issue 5, 2014, Pages 896-904

  Kohan, Donald E ^a   Barton, Matthias ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

chronic kidney disease; diabetic nephropathy

Indexed keywords

AMINO ACID; ATRASENTAN; AVOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GROWTH FACTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NIFEDIPINE; SITAXSENTAN; TAK 044; ENDOTHELIN RECEPTOR;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; LIVER TOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; KIDNEY; METABOLISM; MOLECULARLY TARGETED THERAPY; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELINS; HUMANS; KIDNEY; MOLECULAR TARGETED THERAPY; RECEPTORS, ENDOTHELIN; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84908563167     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.143     Document Type: Short Survey

References (77)

1. Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. New Engl J Med 2013; 369: 2549-2550
2. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169
3. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340
4. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Ann Rev Med 2013; 64: 357-366
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
6. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86: 485-498
7. Kohan DE, Rossi NF, Inscho EW, et al. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91: 1-77
8. Stuart D, Chapman M, Rees S, et al. Myocardial, smooth muscle, nephron and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 2013; 346: 182-189
9. Stuart D, Rees S, Woodward SK, et al. Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol 2012; 13: 166
10. Wesson DE. Endothelin role in kidney acidification. Semin Nephrol 2006; 26: 393-398
11. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008; 4: 490-501
12. Turner JM, Bauer C, Abramowitz MK, et al. Treatment of chronic kidney disease. Kidney Int 2012; 81: 351-362
13. Saleh MA, Pollock JS, Pollock DM. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther 2011; 338: 263-270
14. Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 2012; 23: 652-660
15. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990; 22: 839-842
16. Barton M, Shaw S, dUscio LV, et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238: 861-865
17. Zager RA, Johnson AC, Andress D, et al. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 2013; 84: 703-712
18. Barton M, Tharaux PL. Endothelin and the podocyte. Clin Kidney J 2012; 5: 17-27
19. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Prac Nephrol 2005; 1: 44-54
20. Lenoir O, Milon M, Virsolvy A, et al. ET-B receptors in podocytes promote diabetic glomerulosclerosis with b-catenin and NFkB activation. ET-13 Conference; Tokyo, Japan; 2013, p O-7
21. Ortmann J, Amann K, Brandes RP, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44: 974-981
22. Morigi M, Buelli S, Zanchi C, et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 2006; 169: 1965-1975
23. Morigi M, Buelli S, Angioletti S, et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005; 166: 1309-1320
24. Saleh MA, Boesen EI, Pollock JS, et al. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010; 56: 942-949
25. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389
26. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440-444
27. Speed JS, Pollock DM. Endothelin, kidney disease, and hypertension. Hypertension 2013; 61: 1142-1145
28. Yamauchi T, Ohnaka K, Takayanagi R, et al. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990; 267: 16-18
29. Zhou X, Hurst RD, Templeton D, et al. High glucose alters actin assembly in glomerular mesangial and epithelial cells. Lab Invest 1995; 73: 372-383
30. Collino F, Bussolati B, Gerbaudo E, et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008; 294: F1185-F1194
31. Benigni A, Colosio V, Brena C, et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47: 450-456
32. Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-154
33. Gagliardini E, Corna D, Zoja C, et al. Unlike each drug alone, Lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009; 297: F1448-F1456
34. Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003; 83: 1267-1277
35. Barton M. Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010; 1802: 1203-1213
36. Certikova Chabova V, Vernerova Z, Kujal P, et al. Addition of ETA receptor blockade increases renoprotection provided by renin-Angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sci 2014; (in press
37. Boffa JJ, Tharaux PL, Dussaule JC, et al. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37: 490-496
38. Placier S, Boffa JJ, Dussaule JC, et al. Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant 2006; 21: 881-888
39. Opocensky M, Kramer HJ, Backer A, et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006; 48: 965-971
40. Vernerova Z, Kramer HJ, Backer A, et al. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol 2008; 48: 165-173
41. Kasaab S, Miller MT, Novak J, et al. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998; 31: 397-402
42. Barton M, Vos I, Shaw S, et al. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 2000; 11: 835-845
43. Chade AR, Stewart NJ, Peavy PR. Disparate effects of single endothelin-A and-B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int 2014; 85: 833-844
44. Kelsen S, Hall JE, Chade AR. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol 2011; 301: F218-F225
45. Fligny C, Barton M, Tharaux PL. Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 2011; 172: 120-138
46. Floege J, Hackmann B, Kliem V, et al. Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 1997; 51: 230-243
47. Zhu L, Jiang R, Aoudjit L, et al. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1621-1630
48. Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010; 120: 1084-1096
49. Lattmann T, Shaw S, Munter K, et al. Anatomically distinct activation of endothelin-3 and the L-Arginine/nitric oxide pathway in the kidney with advanced aging. Biochem Biophys Res Commun 2005; 327: 234-241
50. Di Cunto F, Topley G, Calautti E, et al. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 1998; 280: 1069-1072
51. Megyesi J, Price PM, Tamayo E, et al. The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999; 96: 10830-10835
52. Mallamaci F, Parlongo S, Zoccali C. Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 1993; 63: 291-295
53. Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 80: 299-304
54. Lilitkarntakul P, Dhaun N, Melville V, et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011; 216: 217-225
55. Grenda R, Wuhl E, Litwin M, et al. Urinary excretion of endothelin-1 (ET-1), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 2007; 22: 3487-3494
56. Kohan D. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29: 2-26
57. Phisitkul S, Khanna A, Simoni J, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010; 77: 617-623
58. Mahajan A, Simoni J, Sheather SJ, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010; 78: 303-309
59. Pallini A, Hulter HN, Muser J, et al. Role of endothelin-1 in renal regulation of acid-base equilibrium in acidotic humans. Am J Physiol Renal Physiol 2012; 303: F991-F999
60. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193
61. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119
62. Dhaun N, Macintyre IM, Melville V, et al. Effects of endothelin receptor antagonism relate to the degree of renin-Angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009; 54: e19-e20
63. Dhaun N, Ferro CJ, Davenport AP, et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3228-3234
64. Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664
65. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535
66. Smolander J, Vogt B, Maillard M, et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Chin Pharmacol Ther 2009; 85: 628-634
67. Dhaun N, Macintyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779
68. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-Angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763-772
69. Andress DL, Coll B, Pritchett Y, et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012; 91: 739-742
70. De Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2014 (in press
71. Parvanova A, Van Der Meer I, Iliev I, et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013; 1: 19-27
72. Study Of Diabetic Nephropathy With Atrasentan (SONAR) 2013 Available from http://www.clinicaltrials.gov/ct2/show/NCT01858532
73. A Randomized, Double-Blind, Study to Explore the Efficacy and Safety of RE-021 in Focal Segmental Glomerulosclerosis (FONT-3) 2012; http://www.clinicaltrials.gov/ct2/show/NCT01613118?term=endothelin- font-3&rank=1
74. Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO) 2010 Available from http://www.clinicaltrials.gov/ct2/show/NCT01241383? term=endothelin-bosentan-scleroderma&rank=2
75. Penn H, Burns A, Black C, et al. An open label trial of the endothelin receptor antagonist bosentan in scleroderma renal crisis (BIRD-1). Arthritis Rheum 2009; 60 Suppl 10: 451 (abstract
76. Barton M, Kohan DE. Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 2011; 172: 255-260
77. Kohan DE, Cleland JG, Rubin LJ, et al. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 2012; 91: 528-539